Thor Medical ASA: Disclosure of large shareholdings and notification of transaction by close associates of primary insiders

Oslo, Norway, 20 December 2024: Reference is made to the stock exchange announcement by Thor Medical ASA (the "Company") on 11 December 2024 regarding a private placement of new shares to be issued by the Company (the "Private Placement") and a retail offering of new shares (the "PrimaryBid Offering"), and stock exchange announcement by the Company on 12 December 2024 regarding disclosure of share lending.

In connection with the registration of the share capital increase pertaining to tranche 1 of the Private Placement and the PrimaryBid Offering, the manager has redelivered a total of 45,632,920 borrowed shares to Scatec Innovation AS, close associate of primary insider of the Company John Andersen.

During the term of the loan, and prior to the redelivery of the shares, Scatec Innovation AS' shareholding in the Company was reduced to 18,785,012, equivalent to approx. 6.70% of the issued share capital and votes. Upon redelivery of the borrowed shares, Scatec Innovation AS' shareholding in the Company is 64,417,932, equivalent to approx. 22.97% of the issued share capital and votes. Consequently, Scatec Innovation AS has crossed above the 20% threshold pursuant to section 4-2 (1) and (3) of the Norwegian Securities Trading Act.

In addition, Scatec Innovation AS has controlling interest in Scatec Invest II AS and Scatec Invest IV AS, which holds 1,584,324 and 3,165,920 shares in the Company, respectively. Scatec Innovation AS aggregated shareholding is thus 69,168,176, equivalent to approx. 24.7% of the shares and votes in the Company.

This information is subject to disclosure requirements pursuant to the EU Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading Act section and 5-12.

Contacts

Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no - https://www.thormedical.no.